Replies to post #18232 on Biotech Values

[gfp927z]

Rstor1, Yes, figuring that PTIE won't have to pay for manufacturing, marketing, and royalties to Durect, and the deal looks a lot better. Thanks for the input!

[urche]

PTIE valuation

You don't even need 901 or Oxy to justify $16-20/sh today.

Bob, I'm glad you feel that way, because I still feel something is amiss with the agonist/antagonist hypothesis and, I personally would not put much value on the PTIE pipeline other than Remoxy. With today's news, the probability of Remoxy reaching the market is quite high and, finally, I think some reasonable valuations for PTIE can be put forth.
I'll go on record predicting that after disappointing IBS and/or Oxytrex data are released later this year, anyone who wants to own PTIE will be able to do so cheaper than today's price.

Congratulations to anyone who has held PTIE thru all it has been thru.

Urche